Status:
RECRUITING
18F-FSPG PET/CT as a Non-Invasive Imaging Biomarker for Treatment Response to Chemoradiation in Esophageal Cancer
Lead Sponsor:
M.D. Anderson Cancer Center
Conditions:
Esophageal Carcinoma
Eligibility:
All Genders
18+ years
Brief Summary
This study is being done to learn how 18F-FSPG PET/CT scan results may be related to the response to chemotherapy and radiation in patients with esophageal cancer.
Detailed Description
PRIMARY OBJECTIVES: I. Evaluate the ability of 18F-FSPG PET imaging to detect tumors in patients with esophageal cancer.
Eligibility Criteria
Inclusion
- \* ≥ 18 years of age
- Patients with locally advanced esophageal cancer
- Patients with untreated documented carcinoma of the esophagus that is \> 2 cm who are going to receive systemic therapy concurrently with radiation as primary therapy
- Ability to provide written informed consent in accordance with institutional policies
- Female subjects of childbearing potential must have a negative serum or urine pregnancy test within 1 week of the proposed investigational PET/CT scan(s) prior to injection of the investigational radiopharmaceutical
Exclusion
- \* Body weight ≥ 400 pounds or body habitus or disability that will not permit the imaging protocol to be performed
- Pregnant or lactating females
- Have an allergy to intravenous contrast
- eGFR \< 30
Key Trial Info
Start Date :
August 23 2023
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
December 31 2027
Estimated Enrollment :
60 Patients enrolled
Trial Details
Trial ID
NCT06549413
Start Date
August 23 2023
End Date
December 31 2027
Last Update
August 13 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
M D Anderson Cancer Center
Houston, Texas, United States, 77030